This evidence-based, interdisciplinary session will review current evidence and discuss potential strategies for the prevention and monitoring of cisplatin-related ototoxicity. It will include information about pharmacologic interventions using sodium thiosulfate, as well as practical guidance on integrating audiologic surveillance into oncology care models.
Attendees will be able to:
- Describe the pathophysiology of cisplatin-induced ototoxicity and its implications for long-term quality of life in pediatric and adult populations
- Summarize current evidence and clinical guidelines for the use of sodium thiosulfate (STS) as an otoprotective agent during cisplatin chemotherapy
- Describe challenges faced by oncologists in obtaining timely access to audiology services for their patients
- Identify best practices for developing audiology monitoring networks, including interprofessional communication protocols with oncology teams
- Demonstrate knowledge of portable audiologic screening technologies and how these tools can be deployed in oncology clinics, infusion centers, and inpatient settings for ongoing ototoxicity surveillance
